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CT modified radiotherapy planning in a significant percentage 
of patients. 
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Purpose or Objective: Ovarian cancer is a gynecological 
malignancy characterized by a dismal outcome for its 
tendency to metastasize despite aggressive systemic 
therapies, commonly carboplatin and paclitaxel. Among 
recurrent ovarian cancer, patients with oligometastatic 
disease are supposed to have a better prognosis since they 
could benefit from local approaches besides chemotherapy, 
considering also the limited alternative regimens of systemic 
therapy. The aim of our study is to evaluate the role of 
stereotactic body radiotherapy (SBRT) in terms of LC and 
toxicity in a setting of patients with oligometastatic 
recurrent ovarian cancer. 
 
Material and Methods: Between January 2011 and February 
2015, 15 patients (20 lesions) with recurrent oligometastatic 
ovarian carcinoma of any histology underwent SBRT. Toxicity 
and tumor response was scored using Radiation Therapy 
Oncology Group/European Organization for Research and 
Treatment of Cancer Scale. Tumor response was evaluated by 
CT/ PET, according to Response Evaluation Criteria in Solid 
Tumors. 
 
Results: Median age at treatment was 60 years and median 
follow-up was 21 months. The sites of disease were 
abdomino-pelvic lymphnodes (13 lesions), liver metastasis (4 
lesions), lung metastatasis (2 lesions) and para-vaginal mass 
(1 lesion). The SBRT doses were prescribed based on 
dimensions of target volumes and organs at risk constraints as 
follow: for lymphnodal lesions the dose prescription was 36-
45 Gy in 6 fractions and only one case treated with 40 Gy in 4 
fr; for hepatic lesions 61.89 -75 Gy in 3 fractions, for the 
pulmonary lesions both cases received 48 Gy in 4 fractions 
meanwhile in the para vaginal recurrence dose prescription 
was 36 Gy in 6 fractions. None of the patients had grade 3 /4 
acute or late Gu or Gi toxicity. At a median follow-up of 21 
months local control was observed in 85%. Complete 
radiologic response, partial response and progressive disease 
were observed in 12 (60%), 5 (25%) and respectively 3 cases 
(15%). 
 
Conclusion: SBRT is a feasible and well tolerated treatment 
approach in oligo-metastatic ovarian patients, offering a 
good local control. Certainly, additional patients and longer 
follow-up are necessary to confirm the impact of local 
treatment as SBRT in ovarian cancer therapy. 
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Purpose or Objective: This is a concern about hematological 
toxicity (HT) of intensity-modulated radiation therapy (IMRT) 
technique combined with chemotherapy used in the 
treatment of gynecological malignancies due to the high 
volume of low radiotherapy doses given to bone marrow. We 
aimed to determine if pelvic IMRT increased HT and which 
dosimetric parameters were predictors of this toxicity. 
 
Material and Methods: Ninety-nine consecutive cervical 
cancer patients treated with radio-chemotherapy (45-50,4Gy 
with Cisplatin 40mg/m2/week) between IX2011 and V2015 
were included. Fifty patients received three-dimensional 
conformal radiotherapy (3D-CRT) (4-6 fields) and 49 IMRT 
with RapidArc. Target volumes were contoured in accordance 
with RTOG Atlas guidelines. Pelvic bone marrow was defined 
using a computed tomography density-based autocontouring 
algorithm. HT was graded by Common Terminology Criteria 
for Adverse Events, version 4.0 criteria weekly during 
treatment. The rate of occurrence of grade III-IV HT (overall, 
anemia, thrombocytopenia, neutropenia, leucopenia) were 
evaluated in relation with radiotherapy technique, PTV, age, 
mean dose to bone marrow, volumes of bone marrow 
receiving 5, 10, 20, 30, and 40 Gy (V5, V10, V20, V30, and 
V40). The Chi2 test was used to compare HT for each studied 
parameter dichotomized at the median. Differences between 
IMRT and 3D-CRT technique were compared with U-Mann-
Whitney test. 
 
Results: Patients treated with IMRT had significantly lower 
V20, V30, V40, mean bone marrow dose, and PTV volume 
than 3D-CRT patients (p<.00001 for each). The both 
techniques did not differ significantly in age of patients, 
number of chemotherapy cycles given, V5 and V10. Grade III-
IV HT of any kind occurred in 52% of 3D-CRT patients and 30% 
of IMRT patients, p=0.03. Each evaluated threshold of dose 
given to bone marrow predicted significantly occurrence of 
HT. Larger PTV was not predictor of higher HT. 
 
Conclusion: Pelvic IMRT decreased HT of radio-chemotherapy 
for cervical cancer in comparison with 3D-CRT by reduction 
of volume of doses >20Gy given to bone marrow. Even though 
a precise dose threshold for bone marrow was not 
determined, limitation of bone marrow volume defined 
automatically as bone in patients treated with radio-
chemotherapy is warranted. 
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Purpose or Objective: Adjuvant intensity modulated 
radiotherapy (IMRT) for cervical cancer is associated with 
reduced late gastrointestinal toxicity (GI) however it’s impact 
on quality of life (QOL) is not known. The present matched 
pair analysis was performed to compare QOL between three-
dimensional conformal radiation (3DCRT) and IMRT. 
 
Material and Methods: From Jan,2011- Dec,2013 patients 
undergoing adjuvant or salvage radiation with 3DCRT or IMRT 
(with or without concurrent chemotherapy) and vaginal 
brachytherapy were included. Those who received systemic 
chemotherapy or extended field radiation were excluded. 
The study inclusion criteria also necessitated at least 1 year 
of follow up with QOL assessment at at least 2 time points. 
At follow up toxicity was documented using CTCAE version 
3.0 and QOL was measured with EORTC QLQC-30 and Cx-24 
module. The baseline characteristics of two cohorts were 
compared using chi-square test. Raw scores were converted 
into final scores using EORTC recommended conversion and 
linear mixed model was used to evaluate impact of time 
trends and treatment technique on QOL. A 10-point 
difference in QOL score and p≤0.05 was considered relevant 
and statistically significant. All data were analyzed using 
SPSS, version 20.0 and Graph pad Instat. 
 
Results: A total of 64 patients were eligible. Postoperative 
IMRT and 3DCRT was used in 40 and 24 patients respectively. 
The baseline socioeconomic, disease and treatment related 
characteristics were well balanced in both groups rendering 
cohorts eligible for a matched pair analysis. At one year 
there was recovery in most of the QOL domains in both 
cohorts with objective scores reaching baseline levels. The 
